
News|Podcasts|January 17, 2024
Patients Outcomes Impact (POI™): The Evolution of Measuring Patient-Centered Investment
Author(s)ZS Associates
Michael Shaw, JD, and Sharon Suchotliff, MPH, from ZS, discuss why measuring impact through a patient-centric lens is a business imperative for life sciences companies. They explore key considerations for a key challenge when thinking about impact for patients in the real world- the compliant measurement of non-promotional activities, results from an early ZS proof of concept to determine Patient Outcomes Impact (POI™) metrics, and discuss what you can do today to advance POI™ at your organization.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Trending on PharmExec
1
Novo Nordisk Submits NDA to FDA for CagriSema
2
The End of the Rebate Era? What HR Leaders and Pharmacy Consultants Need to Know About Biosimilars
3
Roundup: Harbor BioMed Announces Collaboration and License Agreement with Bristol Myers, Squibb, VYNE Therapeutics Enters Merger Agreement with Yarrow Bioscience
4
Pfizer’s Stock Reacts to Decreases in 2026 Revenue Projections in Full-Year 2026 Guidance Release
5




